Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CULTIVATE: Etrasimod in Moderately to Severely Active Crohn's Disease
NCT04173273Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jan 2020
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 41
01
Overview
A Phase 3 trial of etrasimod in Crohn's disease, sponsored by Pfizer. Started Jan 2020; status: terminated.
02
Drugs
etrasimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04173273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173273.